Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 17, 2025Journal of Current Hematology & Oncology Research

Ten-year journey with myelofibrosis: real-world data and clinical outcomes from a tertiary care center

View Full Paper
Ask AI
Bookmark
Share

Authors

BABerrin Balık AydınAAAydan AkdenizMKMahmut Bakır Koyuncu

Discussion

Loading...

Member takes

Overview

Retrospective analysis of 74 patients with myelofibrosis shows high mortality and unclear impact of ruxolitinib on survival.

Key Points

  • Overall survival for myelofibrosis patients was a median of 6 years with significant mortality observed.
  • Out of 74 patients, 34 deaths occurred during the study, indicating a mortality rate of 45.9%.
  • Retrospective study on myelofibrosis at a tertiary care center analyzed patient data from 2009 to 2019.
  • The unclear effect of ruxolitinib on life expectancy suggests the necessity for innovative treatment options.

Cite This Study

Aydın et al. (2025) studied this question.

synapsesocial.com/papers/68c2368eb210217d64774bbfhttps://doi.org/10.51271/jchor-0063
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A case report of ruxolitinib reversing myelofibrosis2025
  2. 2Significant improvement of bone marrow fibrosis in patients with chronic myeloproliferative neoplasms (CMPN) treated with ruxolitinib.2025
  3. 3Peri-transplant ruxolitinib therapy significantly improves GVHD-free, relapse-free survival rates in transplantation for myelofibrosis2025 · 1 citations
  4. 4Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry2025
  5. 5Real-world treatment landscape and disease burden of myelofibrosis in Taiwan, South Korea, Japan, and Canada2026